摘要
目的探讨唑来磷酸和普伐他汀对绝经后妇女骨质疏松的治疗作用。方法前瞻性研究我院92例绝经后骨质疏松女性患者,随机分成唑来磷酸+普伐他汀组(A组)、唑来磷酸组(B组)和普伐他汀组(C组),分别按照各自的方案治疗并检测各组治疗前后骨密度值、骨钙素含量。结果各组患者治疗前后骨密度值、骨钙素含量的差异有统计学意义(P<0.05),A组患者治疗后骨密度值、骨钙素含量均较B、C组高,差异有统计学意义(P<0.05),但B、C两组患者治疗后骨密度值、骨钙素含量差异无统计学意义(P>0.05)。结论联合使用唑来磷酸和普伐他汀对骨质疏松有更好的治疗作用。
Objective To investigate the treating effect of zoledronate combined with pravastatin on postmenopausal women with osteoporosis. Methods By clinical trial,92 postmenopausal women patients with osteoporosis were randomly divided into 3 groups. The patients were administrated with zoledronate（group A） ,pravastatin（group B） and both of them（group C） ,Bone density（BMD） was assessed by dual energy X-ray absorptiometry,serum osteocalcin（BGP） was assessed by means of enzyme-linked immunosorbent assay（ELISA） . Results Both zoledronate and pravastatin could increase the BMD（P〈0. 05） and BGP（P〈0. 05） level of osteoporosis,especially when zoledronate combined with pravastatin was used（P〉0. 05） . Conclusion Application of pravastatin combined with zoledronate has a better therapeutic effect on osteoporosis.
出处
《中国现代药物应用》
2010年第14期18-19,共2页
Chinese Journal of Modern Drug Application
